Chair: K. Odening (Freiburg im Breisgau), N. Voigt (Göttingen)
| 12:15 | (V96) | Epigenetics and genetics of CPVT – implications for risk stratification |
| L. Fabritz (Birmingham, UK) | ||
| 12:32 | Discussion | |
| 12:37 | (V97) | Novel insights from experimental CPVT models: On molecules, cells and animals |
| S. Lehnart (Göttingen) | ||
| 12:55 | Discussion | |
| 13:00 | (V98) | Cellular mechanisms of CPVT as target for improved drug treatment |
| J. Fauconnier (Montpellier cedex, FR) | ||
| 13:17 | Discussion | |
| 13:22 | (V99) | Do we need ICD-therapy in CPVT after all? |
| C. W. Israel (Bielefeld) | ||
| 13:40 | Discussion |
| 14:00 - 15:30 | Poster DGK Herztage |